Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia

NCT06594965 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT06594965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06594965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2024
Completion date
October 30, 2026
Enrollment
176 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, bone marrow disease, mds, myelodysplastic syndromes